Topic: regenerative medicine
With a multipronged approach and a fresh infusion of $92 million, Tenaya Therapeutics is going after the underlying causes of heart disease.
A Penn team is adapting CAR-T cell therapy to target cardiac fibrosis, and they have promising early results in rodents.
A revised flavonoid could promote the regrowth of functional myelin in mice, scientists at the Oregon Health & Science University have shown.
A self-assembling peptide hydrogel developed by the New Jersey Institute of Technology improved neuronal survival in rats with traumatic brain injury.
A Stanford team has proposed a strategy for coaxing supporting cells in the brain to transform into memory-preserving neurons.
Samumed CEO Osman Kibar discusses regenerative medicine, drugging the Wnt pathway and his company's unorthodox journey.
Prellis Biologics has assembled $8.7 million in new funding alongside positive news from the first transplantation of its vascular tissue scaffolds.
Astellas will develop Frequency's hearing loss drug outside the U.S. in exchange for $80 million upfront and the promise of $545 million down the line.
Trefoil Therapeutics raised $28 million to push its regenerative treatment for corneal dystrophies toward the clinic.
In the first patient to receive its cell implant, Sernova’s insulin-secreting Cell Pouch was able to help maintain glucose levels over two weeks.